← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...
  1. Home
  2. ARMP
  3. P/E History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

ARMP logoArmata Pharmaceuticals, Inc. (ARMP) P/E Ratio History

Historical price-to-earnings valuation from 2013 to 2015

Current P/E
-21.0
Undervalued
5Y Avg P/E
10.1
-308% vs avg
PE Percentile
0%
Low
PEG Ratio
N/A
N/A
TTM EPS$-1.29
Price$10.97
5Y PE Range1.4 - 48.3
Earnings YieldN/A

Loading P/E history...

Valuation Context

How does the current P/E compare to historical and market benchmarks?

vs. 5Y Average
-21.0vs10.1
-308%
Cheap vs History
vs. Healthcare
-21.0vs23.3
-190%
Below Sector
vs. S&P 500
-21.0vs26.1
-180%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 73% EPS growth (1Y)
Export Data

P/E Ratio Analysis

As of March 4, 2026, Armata Pharmaceuticals, Inc. (ARMP) trades at a price-to-earnings ratio of -21.0x, with a stock price of $10.97 and trailing twelve-month earnings per share of $-1.29.

The current P/E is 308% below its 5-year average of 10.1x. Over the past five years, ARMP's P/E has ranged from a low of 1.4x to a high of 48.3x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 23.3x, ARMP trades at a 190% discount to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 190.3x.

Relative to the broader market, ARMP trades at a notable discount to the S&P 500 median P/E of 26.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ARMP DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

Historical P/E Data

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterDatePriceTTM EPSP/E Ratiovs Avg
FY2015 Q2$1309.00$27.1148.3x+380%
FY2015 Q1$2065.00$273.517.5x-25%
FY2014 Q4Wed Dec 31 2014 00:00:00 GM$1435.00$342.114.2x-58%
FY2014 Q3$1512.00$793.201.9x-81%
FY2014 Q2Mon Jun 30 2014 00:00:00 GM$3066.00$541.205.7x-44%
FY2014 Q1Mon Mar 31 2014 00:00:00 GM$4046.00$2768.581.5x-85%
FY2013 Q4$3500.00$2576.361.4x-86%

Average P/E for displayed period: 10.1x

See ARMP's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is ARMP Undervalued?

See our Bear / Base / Bull DCF models and intrinsic value estimates.

View Valuation

Compare ARMP vs AGIO

See how ARMP stacks up against sector leader Agios Pharmaceuticals, Inc..

Start Comparison

Frequently Asked Questions

Is ARMP stock overvalued or undervalued?

ARMP trades at -21.0x P/E, below its 5-year average of 10.1x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.

How does ARMP's valuation compare to peers?

Armata Pharmaceuticals, Inc. P/E of -21.0x compares to sector median of 23.3x. The discount suggests lower growth expectations or higher risk.

What is ARMP's PEG ratio?

ARMP PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2013-2015.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.

P/E Ratio Over Time

P/E ratio calculated as closing price divided by trailing 12-month diluted EPS at each quarter end.